title: Pharmacoproteomics in cardiac hypertrophy and atherosclerosis.
abstract: Proteomics applications to study the molecular effects of drug administration (pharmacoproteomics) on left ventricular hypertrophy (LVH) and atherosclerosis are here reviewed. In most cases, an absence of complete normalization after treatment is revealed, in contrast to what is reported by classical approaches.
authors.affiliation: Laboratory of Renal Physiopathology, Nephrology Department, Gregorio Marañón University General Hospital, Madrid, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Lazaro
authors.forename: Gloria
authors.initials: G
authors.lastname: Alvarez-Llamas
authors.forename: Julio
authors.initials: J
authors.lastname: Gallego-Delgado
authors.forename: Fernando
authors.initials: F
authors.lastname: de la Cuesta
authors.forename: Julio
authors.initials: J
authors.lastname: Osende
authors.forename: M Eugenia G
authors.initials: ME
authors.lastname: Barderas
authors.forename: Fernando
authors.initials: F
authors.lastname: Vivanco
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy* / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D020543:Proteome